Self-adjuvanting Yersinia outer membrane vesicle as a vaccine against plague, anthrax and pseudomonas infection
US12214030B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Sep 23, 2021 |
| Grant date | Feb 4, 2025 |
| Priority date | — |
| Expiry date | Jul 26, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55594
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A vaccine platform using a Yersinia pestis mutant synthesizing an adjuvant form lipid A (monophosphoryl lipid A, MPLA) for the increased biogenesis of bacterial outer membrane vesicles (OMVs). To enhance the immunogenicity of the OMVs, an Asd-based balanced-lethal host-vector system was constructed to oversynthesize the LcrV antigen of Y. pestis, raise the amounts of LcrV enclosed in OMVs by Type II secretion system, and eliminate harmful factors like plasminogen activator (Pla) and murine toxin from the OMVs. Vaccination with OMVs containing MPLA and increased amounts of LcrV with diminished toxicity afforded complete protection in mice against subcutaneous challenge and intranasal challenge and was significantly superior to that resulting from vaccination with LcrV/alhydrogel. Additionally, the Yersinia OMV can be used as a platform to deliver the heterologous antigens of Bacillus anthraces. Vaccination with multiantigenic self-adjuvanting bionanoparticles from Pseudomonas was also successfully tested in connection with Pseudomonas aeruginosa.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.